SEC Form 4	
------------	--

П

I

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

hours per response:	0.5
Estimated average burd	len
	3235-0287

1. Name and Address of Reporting Person [*] Ashlock Melissa A.			2. Issuer Name and Ticker or Trading Symbol <u>aTYR PHARMA INC</u> [LIFE]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify
(Last) 3545 JOHN HC	(First) PKINS CO	(Middle) URT, SUITE 250	3. Date of Earliest Transaction (Month/Day/Year) 10/01/2015	X Onicer (give the Other (specify below) below) See Remarks
(Street) SAN DIEGO	СА	92121	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting
(City) (State) (Zip)		(Zip)		Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (II 3, 4 and	ve es d ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (right to buy)	\$10.24	10/01/2015		А		30,000		(1)	10/01/2025	Common Stock	30,000	\$0.00	30,000	D	
Employee Stock Option (right to buy)	\$10.24	10/01/2015		A		12,976		(2)	(2)	Common Stock	12,976	\$0.00	12,976	D	

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on November 1, 2015, such that this option will be fully exercisable on October 1, 2019. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

2. The shares subject to this option shall vest and become exercisable, if at all, in 28 equal monthly installments upon the achievement of certain performance goals, which must be achieved by October 1, 2017, or such option will be subject to immediate forfeiture. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

Remarks:

SVP, Translational Medicine and Therapeutics

/s/ Nancy Krueger, as Power of 10/05/2015

<u>Attorney</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.